Normodorm (Doxylamine Hydrogen Succinate)

Doxylamine hydrogen succinate, the active ingredient in Normodorm, is a first‑generation H1 antihistamine presented as an oral dosage form for oral use. It is employed to relieve symptoms of allergic rhinitis and to provide short‑term relief of insomnia in adults. GNH USA supplies Normodorm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Normodorm, a first‑generation H1 antihistamine, is used for conditions mediated by histamine release and central sedation pathways.

Insomnia: helps initiate and maintain sleep during short‑term treatment. Allergic rhinitis: reduces nasal congestion, sneezing, itching and watery discharge. Motion sickness: prevents nausea and vomiting associated with travel or vestibular disturbances.

Common Side Effects: - Drowsiness or excessive sleepiness. - Dry mouth and throat. - Dizziness or light‑headedness. - Blurred vision. - Constipation or gastrointestinal discomfort. - Urinary retention, especially in older adults.

Serious or Rare Side Effects: - Severe allergic reactions such as anaphylaxis or angioedema. - Cardiac arrhythmias or palpitations. - Seizures or convulsive episodes. - Hallucinations, confusion or delirium. - Hepatic injury manifested by jaundice or elevated liver enzymes. - Extrapyramidal symptoms or severe movement disorders.

Before using Normodorm, consider the following safety measures.

Assess sedation risk: evaluate patient’s need for alertness (e.g., driving, operating machinery). Avoid concurrent CNS depressants: limit use with alcohol, opioids, or benzodiazepines. Use caution in elderly: increased susceptibility to anticholinergic effects and falls. Pregnancy and lactation: consult a healthcare professional before use. Monitor for allergic reactions: discontinue if signs of rash, swelling, or breathing difficulty occur. Store at ambient temperature: keep in the original container, protect from moisture and heat.

Normodorm may interact with several drug classes; monitoring is advised.

Major Interactions (Avoid): - Alcohol: additive central nervous system depression. - Opioid analgesics: heightened sedation and respiratory depression. - Benzodiazepines: increased risk of profound drowsiness. - Other anticholinergic agents: amplified anticholinergic burden. - Monoamine oxidase inhibitors: potential for hypertensive episodes.

Moderate Interactions (Monitor Closely): - Other antihistamines: cumulative sedation. - Tricyclic antidepressants: enhanced anticholinergic side effects. - Antipsychotics: possible increase in sedation. - Antacids: may affect absorption of the oral formulation. - CNS stimulants: may counteract sedative effect, requiring dose adjustment.